BAT Annual Performance: Revenue down 5.2% from Last Year, Driven by New Product Categories

BAT by 2FIRSTS.ai
Feb.14
BAT Annual Performance: Revenue down 5.2% from Last Year, Driven by New Product Categories
BAT announces annual financial results with revenue of 258.67 billion pounds, down 5.2% from last year, driven by new product categories.

On February 13, British American Tobacco (BAT) released its annual performance report on its official website, covering the period ending December 31, 2024.

BAT Annual Performance: Revenue down 5.2% from Last Year, Driven by New Product Categories
BAT's full-year performance in 2024 (as of December 31, 2024) Source: BAT official website.


As of December 31, 2024, BAT's revenue was £25.867 billion, a decrease of 5.2% compared to the same period in 2023; operating profit was £2.736 billion, with £6.2 billion set aside in 2024 for a proposed settlement in Canada, while 2023 was mainly affected by negative impacts from disposable impairment charges in the US; new category revenue was £3.432 billion. New category tobacco revenue accounted for 17.5% of the company's total revenue, an increase of 1% from the 2023 fiscal year. The number of new category tobacco users reached 29.1 million, an increase of 3.6 million from the end of 2023.

BAT Annual Performance: Revenue down 5.2% from Last Year, Driven by New Product Categories
Translation into English: BAT's performance in new product categories | Image source: BAT official website


The core contents of the report are as follows:


Income decreased by 5.2% due to the sale of businesses in Russia and Belarus in September 2023, as well as unfavorable foreign exchange rates. Organic revenue growth was 1.3% (calculated at fixed exchange rates), driven by an 8.9% increase in revenue from new product categories. Total revenue from combustible organic products increased by 0.1% (calculated at fixed exchange rates) as a 5.3% increase in organic product prices/composition was offset by a 5.2% decrease in sales volume. Adjusted organic operating profit increased by 1.4% (calculated at fixed rates), driven by AME and APMEA. Adjusted for organic and constant exchange rates, new categories contributed an additional £251 million, with a current category profit margin of 7.1%, up 7.1% from 2023. Free cash flow was £79.01 billion; adjusted net debt/adjusted EBITDA decreased by 0.13 times to 2.44 times (a decrease of 0.3 times calculated at fixed rates). Dividend increased by 2.0% to 240.24 pence, with plans to repurchase £9 billion in shares by 2025. The launch of Omni™ aims to help achieve a smoke-free world.


Sales of e-cigarettes have dropped by 5.9%, with adjusted revenue decreasing by 2.5% to £1.765 billion. In the US market, the market share value of e-cigarettes is at 50.2%, a 2.0% decrease from 2023. This is primarily due to the growth of illegal disposable e-cigarette products in the US and Canada, as well as the lack of enforcement of regulations on illegally sold products following a ban in Quebec province.


In 2024, sales of heated tobacco products decreased by 11.6%, and revenue decreased by 7.6%. However, when calculated at constant organic exchange rates, revenue increased by 5.8% to 972 million pounds. The market share is at 16.7%, which is a decrease of 40 basis points from 2023. The new product glo Hyper Pro has helped improve the organic financial performance.


In 2024, sales of modern oral tobacco products increased by 55.0%, with revenue growing by 46.6%. Calculated at constant organic exchange rates, the growth is 51.0% to £814 million. In the US market, the market share of modern oral tobacco is 6.6%, an increase of 2.1% compared to 2023.


BAT CEO Tadeu Marroco stated,


The year 2024 was a year of investment for our company, and our performance was in line with expectations. We continued our transformation this year, with 3.6 million new adult users of our new tobacco products. Currently, the total number of users of our new tobacco products has reached 29.1 million people, accounting for 17.5% of the company's total revenue, an increase of 1% from the previous fiscal year. Our sales accelerated in the second half of the year, thanks to the innovation of new product categories, business investments targeting the US market, and the release of related wholesaler inventory changes.


We have focused on quality growth and achieved higher returns through more targeted investments in all three new product categories, leading to a transformational improvement in our European operations. We have made further progress in increasing the profitability of new product categories, particularly excelling in modern oral care products.


In the United States, despite facing challenges from the macroeconomic environment and illegal disposable e-cigarette products, our targeted investments have strengthened our business. Through strategic business actions, our execution has been enhanced and performance is starting to improve, especially in the area of modern oral care products, where we have also identified untapped growth opportunities.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Reuters: BAT to Launch Synthetic Nicotine Vape Vuse One in U.S., Hitting Shelves in Three States from Late September
Reuters: BAT to Launch Synthetic Nicotine Vape Vuse One in U.S., Hitting Shelves in Three States from Late September
British American Tobacco (BAT) plans to pilot sales of its disposable synthetic nicotine vape, Vuse One, in the United States, with launches expected in South Carolina, Florida, and Georgia in late September. The product has not yet received approval from the U.S. Food and Drug Administration (FDA). According to Reuters, this move marks a major shift in BAT’s stance after years of opposing the sale of unauthorized vapes. The company said the product will be distributed through major national ret
Aug.21 by 2FIRSTS.ai
Shunho Half-Year Report: New Tobacco Revenue Up 278% YoY to 10.2 Million Yuan, E-Cigarette Segment Revenue 15.59 Million Yuan
Shunho Half-Year Report: New Tobacco Revenue Up 278% YoY to 10.2 Million Yuan, E-Cigarette Segment Revenue 15.59 Million Yuan
In the first half of 2025, Shanghai Shunho New Materials Science & Technology Co., Ltd. recorded revenue of 619 million yuan, down 12.19% year-on-year, and net profit of 33.3 million yuan, up 23.11% year-on-year. Printed products and metallized paper remained the company’s main revenue drivers, but the new tobacco business delivered standout growth, generating 10.2 million yuan in revenue—a surge of 277.83% compared with the same period last year. The e-cigarette segment posted revenue of 15.59
Aug.15 by 2FIRSTS.ai
Comparing the UK's Approved E-cigarette Lists (June-August): E-liquids and pods remain the mainstays, while open-system devices saw an accelerated release of new products in August
Comparing the UK's Approved E-cigarette Lists (June-August): E-liquids and pods remain the mainstays, while open-system devices saw an accelerated release of new products in August
Based on the latest data from the MHRA, e-cigarette registrations in the UK showed a "peak in July, drop in August" trend. E-liquids and pods consistently made up about 90% of the total. While pre-filled pod systems were the most common, open-system device registrations notably increased in August.
Sep.04 by 2FIRSTS.ai
Singapore Government Rebuts Vape Advocacy Group Criticism, Says It Is Linked to Tobacco Companies
Singapore Government Rebuts Vape Advocacy Group Criticism, Says It Is Linked to Tobacco Companies
Singapore’s Home Affairs and Law Minister K. Shanmugam rejected claims from the Coalition of Asia Pacific Tobacco Harm Reduction Advocates (Caphra) that the country’s tough vaping ban is “fearmongering.” He stressed that such arguments mirror those used by drug legalization advocates and pointed out that the group is linked to the tobacco industry.
Sep.01 by 2FIRSTS.ai
Research Brief | Current Use of Cigarettes, E-Cigarettes, and Cannabis Is Significantly Associated with Xerostomia
Research Brief | Current Use of Cigarettes, E-Cigarettes, and Cannabis Is Significantly Associated with Xerostomia
About 9.7% of 29,721 U.S. adults (18+) surveyed in 2022–2023 reported their mouth felt dry “frequently” or “always.” After multivariable adjustment, past-30-day use of cigarettes (AOR ≈ 1.52), e-cigarettes (≈ 1.46), or cannabis (≈ 1.57) was each linked to higher odds of xerostomia. Daily use showed stronger associations (cigarettes ≈ 1.67; e-cigarettes ≈ 1.80; cannabis ≈ 2.15). Concurrent use of all three products had the highest odds (AOR ≈ 3.80). The authors suggest dental professionals factor
Sep.12 by 2FIRSTS.ai
The U.S. FDA has launched a pilot program for PMTA review of nicotine pouches to expedite the approval process and enhance regulatory efficiency
The U.S. FDA has launched a pilot program for PMTA review of nicotine pouches to expedite the approval process and enhance regulatory efficiency
In Sept 2025, the US FDA launched a nicotine pouch PMTA pilot to boost review efficiency, streamline processes and uphold strict scientific standards. Based on the "tobacco product health risk continuum" concept, it shortens cycles by focusing on key product factors and enhancing real-time communication with applicants. The FDA also urges child-resistant packaging to tackle kids’ accidental exposure, emphasizes scientific review for new tobacco products, and has approved 20 nicotine pouches so f
Sep.19 by 2FIRSTS.ai